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Abstract. 
 
The nuclear factor of activated T cells
(NFAT) family of transcription factors regulates the de-
velopment and differentiation of several tissue types.
Here, we examine the role of NFATC2 in skeletal muscle
 
by analyzing adult NFATC2
 
2
 
/
 
2 
 
mice. These mice exhibit
reduced muscle size due to a decrease in myoﬁber cross-
sectional area, suggesting that growth is blunted. Muscle
growth was examined during regeneration after injury,
wherein NFATC2-null myoﬁbers form normally but
display impaired growth. The growth defect is intrinsic
 
to muscle cells, since the lack of NFATC2 in primary mus-
cle cultures results in reduced cell size and myonuclear
number in myotubes. Retroviral-mediated expression of
NFATC2 in the mutant cells rescues this cellular pheno-
type. Myonuclear number is similarly decreased in
 
NFATC2
 
2
 
/
 
2 
 
mice. Taken together, these results impli-
cate a novel role for NFATC2 in skeletal muscle growth.
We demonstrate that during growth of multinucleated
muscle cells, myoblasts initially fuse to form myotubes
with a limited number of nuclei and that subsequent
nuclear addition and increases in myotube size are con-
trolled by a molecular pathway regulated by NFATC2.
Key words: NFATC2 • myotube • muscle growth •
nuclear number • fusion
 
Introduction
 
Calcium is an important regulator of skeletal muscle physi-
ology. Increases in intracellular calcium can activate the
calmodulin-regulated phosphatase calcineurin. Calcineurin-
dependent pathways have been implicated in expression of
muscle-specific genes (Friday and Pavlath, 2001), myoblast
differentiation (Delling et al., 2000; Friday et al., 2000),
skeletal muscle hypertrophy (Musaro et al., 1999; Semsarian
et al., 1999; Dunn et al., 2000), and regulation of slow myofi-
ber-specific gene expression (Chin et al., 1998; Bigard et
al., 2000; Delling et al., 2000; Naya et al., 2000).
One of the downstream targets of calcineurin is the nuclear
factor of activated T cells (NFAT)
 
1
 
 family of transcription
factors (Rao et al., 1997). This family consists of four calcium-
sensitive members, NFATC1–4. Under basal conditions,
NFAT proteins are phosphorylated and localized to the
cytoplasm. In response to increases in intracellular calcium,
calcineurin becomes activated and dephosphorylates NFAT
proteins, thereby allowing their nuclear translocation. Once
 
in the nucleus, NFAT proteins, in association with other
transcription factors, bind to a consensus DNA sequence
and activate gene transcription. Rephosphorylation of
NFAT proteins by several kinases results in nuclear export.
Although originally described in T cells, recent evidence
suggests that this family of transcription factors regulates
development of several tissue types (de la Pompa et al.,
1998; Ho et al., 1998; Ranger et al., 1998a,b, 2000; Kegley
et al., 2001). Different NFAT proteins have distinct func-
tions in both developing and postnatal tissues as revealed
by the study of mice with targeted mutations in specific
NFAT genes. Other studies indicate that multiple types of
NFAT proteins can be expressed in a tissue, but only during
specific stages of development do individual NFAT pro-
teins undergo nuclear translocation in response to increases
in intracellular calcium. Such developmental specificity in
nuclear translocation is observed in T cells (Adachi et al.,
2000) and skeletal muscle cells (Abbott et al., 1998; Delling
et al., 2000). These results imply that different NFAT pro-
teins may regulate specific sets of genes required for distinct
phases of tissue development.
During myogenesis in vitro
 
,
 
 mononucleated myoblasts
are induced to withdraw from the cell cycle by a decrease
in growth factors, initiate muscle specific gene expression,
and subsequently fuse with one another to form multi-
nucleated myotubes. Myotubes undergo further maturation
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as evidenced by increases in size and changes in expression
of contractile proteins. The various stages of myogenesis,
myoblast, nascent myotube, and mature myotube, are not
associated with differences in the amounts or types of
NFAT proteins expressed (Abbott et al., 1998). However,
treatment of muscle cells at different stages of myogenesis
with the calcium ionophore ionomycin resulted in nuclear
translocation of NFATC3 only in myoblasts, and NFATC1
and NFATC2 only in myotubes (Abbott et al., 1998). The
nuclear translocation of NFATC2 was restricted to newly
formed myotubes. This limited activation of NFATC2 sug-
gested that NFATC2 might play a role in regulating the
growth of multinucleated muscle cells.
During development of skeletal muscle tissue, myo-
blasts differentiate and fuse together to form multinucle-
ated myofibers, which are analogous to myotubes in vitro.
After myofiber formation during embryogenesis, the size
of individual myofibers greatly increases during the imme-
diate postnatal period. Satellite cells are a population of
quiescent muscle precursor cells that exist within postnatal
muscle tissue. During periods of growth, satellite cells re-
enter the cell cycle and fuse with adjacent myofibers,
thereby increasing the number of myonuclei within the
myofiber (Moss and Leblond, 1971). Myonuclei exist
within a common cytoplasm and are thought to regulate
the expression of individual proteins for a defined amount
of cytoplasm. This concept of a “myonuclear domain” sug-
gests that the number of myonuclei limits the size of a
myofiber (Allen et al., 1999). Supporting this theory, the
fusion of satellite cells with myofibers is required for mam-
malian postnatal growth (Darr and Schultz, 1989; Rosen-
blatt and Parry, 1993; Mozdziak et al., 2000) and hypertro-
phy (Rosenblatt et al., 1994; Phelan and Gonyea, 1997;
Barton-Davis et al., 1999). However, the molecular mech-
anisms that regulate the addition of myonuclei during
muscle growth are not well defined.
The differential regulation of NFATC2 during myogen-
esis led us to examine its role in the skeletal muscle of
NFATC2
 
2
 
/
 
2 
 
mice. These mice have demonstrated that
NFATC2 regulates development and differentiation of
several tissue types. T cells from NFATC2
 
2
 
/
 
2 
 
mice (Hodge
et al., 1996; Xanthoudakis et al., 1996) hyperproliferate
and have abnormal cytokine production. In addition,
chondrogenesis is induced in extraarticular tissues of older
mice lacking NFATC2, implicating NFATC2 as a repres-
sor of cartilage cell growth and differentiation (Ranger et
al., 2000). In this report, we demonstrate a role for
NFATC2 in skeletal muscle growth. We demonstrate that
during growth of multinucleated muscle cells, myoblasts
initially fuse to form myotubes with a limited number of
nuclei and that subsequent nuclear addition and increases
in myotube size are controlled by a molecular pathway
regulated by NFATC2.
 
Materials and Methods
 
Animals
 
NFATC2
 
2
 
/
 
2 
 
mice were generated by heterozygous or homozygous mat-
ings of mice carrying a targeted disruption in the NFATC2 gene leading to
a loss of function mutation (Hodge et al., 1996). NFATC3
 
2
 
/
 
2 
 
mice were
generated by heterozygous matings of mice carrying a targeted disruption
in the NFATC3 gene (Oukka et al., 1998). Wild-type mice controls for
each of the mutant mice were generated from heterozygous matings. Mice
 
were genotyped by PCR analyses of tail DNA (Hodge et al., 1996; Oukka
et al., 1998). Male mice between 8 and 12 wk of age were used for these
studies. All animals were handled in accordance with the institutional
guidelines of Emory University.
 
Collection of Muscles and Morphometric Measurements
 
Tibialis anterior (TA), soleus, and masseter muscles were collected using
standardized dissection methods, embedded in TBS tissue freezing me-
dium (Fisher Scientific), and frozen in isopentane cooled in liquid nitro-
gen. For histological analyses, 10–12 serial 14-
 
m
 
m sections were collected
along the entire length of the muscle at 400–500-
 
m
 
m intervals and stained
with hematoxylin and eosin. All analyses and photography were per-
formed on an Axioplan (ZEISS) microscope equipped with a video cam-
era and Scion Image and Adobe Photoshop
 
®
 
 software.
The cross-sectional area (CSA) of myofibers was determined in the so-
leus, TA, and masseter muscles of wild-type and NFATC2
 
2
 
/
 
2 
 
mice. For
the soleus, the CSA of sections throughout the soleus muscles was mea-
sured using computer-assisted morphometric measurements, and the re-
gion spanning the belly of the soleus was subsequently used for all further
analyses described below. For the masseter and TA, anatomical markers
of each muscle were used to find the same region in different samples, and
these sections were subsequently used for analysis. The CSA of individual
myofibers in the masseter and TA was determined by capturing an image
in the center of each section and analyzing 100–250 myofibers within this
307,200-
 
m
 
m
 
2
 
 field.
TA muscles were subject to a standardized local freeze damage as de-
scribed previously (Pavlath et al., 1998). In experiments analyzing regen-
erating TA muscles, sections containing the largest area of damage were
selected for measurements. The core of the damaged area, as defined by
the region that was the least regenerated, was visualized, and the image
was captured to a computer screen. The number of centrally nucleated
myofibers in this 307,200-
 
m
 
m
 
2
 
 field was determined on day 7 after injury.
In addition, the CSA of individual regenerating myofibers was also mea-
sured at various time points after damage. Myofibers with CSA smaller
than 100 
 
m
 
m
 
2
 
 were not included in the analysis so as not to mistake regen-
erating myofibers for mononucleated cells in the damaged area.
 
Immunohistochemistry
 
To analyze particular fiber types, cross sections of soleus muscles were
stained with antibodies against type 1 (BA-D5) (Schiaffino et al., 1998)
and type II (My32) (Sigma-Aldrich) myosin heavy chain (MyHC) as de-
scribed (Kegley et al., 2001).
To quantify the number of myonuclei in wild-type and NFATC2
 
2
 
/
 
2
 
 so-
leus muscles, duplicate sections were incubated in antibody against dystro-
phin (MANDYS8, 1:400) (Sigma-Aldrich) for 1 h at room temperature or
4
 
8
 
C overnight. After washing in TNT (0.1 M Tris-HCl, pH 7.5, 0.15 M
NaCl, 0.05% Tween 20), the sections were incubated in Texas red–conju-
gated goat anti–mouse IgG (1:50) (Cappel). After further washing in TNT,
the sections were fixed in 2% formaldehyde for 10 min at room tempera-
ture. The sections were then washed in TNT and mounted in Vectashield
mounting medium containing DAPI (Vector Laboratories). Nuclei within
the dystrophin-positive sarcolemma were counted for 100–150 myofibers,
and the number of myonuclei was expressed per 100 myofibers.
 
Cell Culture
 
Primary cultures were derived from TA muscles of adult wild-type or
NFATC2
 
2
 
/
 
2 
 
mice 2 d after induced muscle damage (Pavlath et al., 1998),
and myoblasts were purified to 
 
.
 
99% in selective medium (Rando and
Blau, 1994). Myoblasts were grown in growth medium (Ham’s F10, 20%
FBS, 5 ng/ml bFGF, 200 U/ml penicillin G, 200 
 
m
 
g/ml streptomycin) on
collagen or entactin-collagen-laminin–coated (Upstate Biotechnology)
dishes in a humidified 5% CO
 
2
 
 atmosphere at 37
 
8
 
C. Differentiation was
induced by switching confluent myoblast cultures grown on E-C-L–coated
dishes to low serum, low mitogen differentiation medium (DM: DME, 2%
horse serum, 200 U/ml penicillin G, 200 
 
m
 
g/ml streptomycin) for 48–72 h.
 
In Vitro Nuclear Number Assays
 
Primary myoblasts were plated at 3 
 
3
 
 10
 
5
 
 cells per well of 6-well dishes.
After 2 h, cells were placed in DM and allowed to differentiate for 48–72 h
before fixation in 3.7% formaldehyde. To identify multinucleated myo-
tubes, cells were washed in PBS and incubated with blocking buffer con-
taining 5% goat serum, 0.5% BSA, and 0.25% Triton X-100 in PBS for 1 h
at room temperature, followed by incubation with an antibody against em- 
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bryonic MyHC (EMyHC) (F1.652, neat hybridoma supernatant; Develop-
mental Studies Hybridoma Bank) for 1 h at room temperature. Cells were
washed in PBS/Tween and then incubated in biotinylated goat anti–mouse
IgG (1:200) (Jackson ImmunoResearch Laboratories). Antibody binding
was detected using Vectastain Elite ABC reagent (Vector Laboratories)
and diaminobenzidine. The number of nuclei within individual myotubes
(
 
$
 
2 nuclei) was counted for 50–200 myotubes. Myotubes were grouped
into two categories, those with two to four nuclei and those with five or
more nuclei. The percentage of myotubes in each category was calculated.
 
Retroviral Plasmids, Retroviral Production,
and Infection
 
A retroviral vector expressing full-length human NFATC2 was created by
PCR amplification of NFATC2 cDNA from the vector pREP4-NFATC2
to create a 2.8-kb product (Ranger et al., 2000). The forward primer con-
sisted of an SrfI site followed by bases 224–241 of the human NFATC2
mRNA (sequence data available from GenBank/EMBL/DDBJ under ac-
cession number U43342), whereas the reverse primer contained an SalI
site and bases 2978–2998. PCR was performed using the Expand Long
Template PCR system (Roche), and the PCR product was digested with
SrfI and SalI. The amplified NFATC2 cDNA was then cloned into a basic
retroviral vector in which expression of NFATC2 is driven by the retrovi-
ral 5
 
9
 
 long terminal repeat. Production of infectious retrovirus and infec-
tion of primary myoblasts were performed as described previously (Ab-
bott et al., 1998). The efficiency of one round of retroviral infection is
estimated at 
 
.
 
60 and 
 
.
 
90% after two rounds based on visualization of
cells infected with vectors containing green fluorescent protein.
 
Reporter Assays
 
Myoblasts in 24-well plates were infected by two rounds of infection with
a combination of either control or NFATC2 retroviruses and an NFAT-
responsive reporter retrovirus (Abbott et al., 1998). 24 h after the last in-
fection, the medium was replaced with DM, and the cells were allowed to
differentiate for 48 h. Cells were collected and assayed for luciferase as
described previously (Abbott et al., 1998).
 
Immunoblotting
 
Cells were lysed with RIPA-2 (50 mM Tris-HCl, pH 8.0, 150 mM NaCl,
1% NP-40, 0.5% deoxycholic acid, 0.1% SDS) containing protease inhibi-
tors (Mini Complete; Roche). Equal amounts of protein (10 
 
m
 
g/lane)
(Bradford, 1976) were separated by SDS-PAGE and transferred electro-
phoretically to a polyvinylidene fluoride membrane (Millipore). Immuno-
blots were performed as described (Friday et al., 2000), and antibody
binding was detected using enhanced chemiluminesence.
 
Northern Blotting
 
RNA was prepared from TA muscles using Trizol Reagent (Life Technol-
ogies) following the manufacturer’s protocol. RNA (10 
 
m
 
g) was separated
on 1% agarose-formaldehyde gels and transferred to nylon membranes.
Membranes were hybridized with random-primed cDNA probes (Re-
diprime II; Amersham Pharmacia Biotech) labeled with [
 
a
 
-
 
32
 
P]dCTP in
Rapid-hyb buffer (Amersham Pharmacia Biotech). After high stringency
washing, membranes were visualized by autoradiography.
 
Relative Reverse Transcription PCR
 
RNA was isolated using Trizol Reagent (Life Technologies) from wild-
type and NFATC2
 
2
 
/
 
2 
 
myoblasts in growth medium. Reverse transcription
(RT)-PCR was performed in duplicate for each sample using primers
specific for NFATC1 (sense, 5
 
9
 
-TCCGGCGCATGCGAGCCGTCATC-
GACTGTGCTGGGATCCTGA-3
 
9
 
; antisense, 5
 
9
 
-GGACCCGGGTCA-
ATTGGCAGGAAGGTACGTGAAACG-3
 
9
 
), NFATC4 (sense, 5
 
9
 
-
GAGGAGCCCCTACCGGACTCATC-3
 
9
 
; antisense, 5
 
9
 
-AAGGGG-
CGGGGAAGGAAGG-3
 
9
 
), and NFATC3 (sense,
 
 
 
5
 
9
 
-CCCAAGAA-
GAATCAGAAGACTGTG-3
 
9
 
;
 
 
 
antisense,
 
 
 
5
 
9
 
-GCTCTAAAGATGGC-
TCCGTGCTTAAGG-3
 
9
 
). All RT reactions were performed using 2.5 
 
m
 
g
of total RNA, and all PCR products were amplified in their linear
range. To quantify the amplicons, the PCR reactions were spiked with
[
 
a
 
-
 
32
 
P]dCTP (specific activity 3,000 Ci/mmol) (ICN Biomedicals), and
18S rRNA was used as an internal control in each sample using Quan-
tumRNA 18S primers (Ambion). The products were resolved using
6% nondenaturing PAGE, and individual band intensities in the dried
gel were determined using a PhosphorImager (Molecular Dynamics).
 
The density of the amplicons for each NFAT isoform was normalized
to the density of the 18S rRNA amplicon and expressed as arbitrary
units.
 
Results
 
Myofiber CSA Is Decreased in NFATC2
 
2
 
/
 
2 
 
Mice
 
Our previous studies in cultured muscle cells indicated that
individual NFAT isoforms are specifically induced to un-
dergo nuclear translocation in response to changes in intra-
cellular calcium at different stages in myogenesis (Abbott
et al., 1998). Such activation of NFATC2 occurred only in
small nascent myotubes, suggesting that NFATC2 may
play a role in regulating growth of differentiated muscle
cells. To test this hypothesis in vivo, we analyzed the soleus
muscles from adult wild-type and NFATC2
 
2
 
/
 
2 
 
mice. So-
leus muscles were examined because in BALB/c mice this
muscle is composed of approximately equal amounts of
slow and fast myofibers (Kegley et al., 2001), allowing us to
determine if NFATC2 has similar roles in different fiber
types. As seen in the top of Fig. 1 A, the CSA of soleus
muscles from NFATC2
 
2
 
/
 
2 
 
mice is smaller than wild-type
muscles. This size difference correlates with a decrease in
the CSA of individual myofibers (Fig. 1 A, bottom). To de-
termine if type I or type II myofibers are differentially af-
fected by the absence of NFATC2, the CSA of myofibers
expressing type I and type II MyHC was measured. The
CSA of both type I and type II myofibers is decreased sig-
nificantly in NFATC2
 
2
 
/
 
2
 
 mice (Fig. 1 B) with a 44 and
33% decrease, respectively. These results suggest that
NFATC2 plays a role in regulating myofiber size.
The CSA of an entire muscle is affected not only by the
size of individual myofibers but also by the number of myofi-
bers. We have shown previously that muscles of adult
NFATC3
 
2
 
/
 
2
 
 mice are smaller than wild-type muscles due to
a decrease in the number but not the CSA of myofibers
(Kegley et al., 2001). This decrease in myofiber number is a
result from a defect in myofiber formation during embryonic
development. Thus, we analyzed the total number of myofi-
bers in soleus muscles from adult wild-type and NFATC2
 
2
 
/
 
2
 
mice to determine if NFATC2 also plays a role in regulating
myofiber number. No difference in the number of myofibers
is observed between wild-type and NFATC2
 
2
 
/
 
2
 
 mice (Fig. 1
C). Thus, in direct contrast to NFATC3
 
2
 
/
 
2
 
 mice, the smaller
size of NFATC2
 
2
 
/
 
2 
 
soleus muscles is due to a decrease in the
CSA and not in the number of myofibers. These data suggest
that myofiber formation during embryogenesis is normal in
NFATC2
 
2
 
/
 
2
 
 mice but that prenatal and postnatal growth of
myofibers is altered.
Since calcineurin-dependent signaling pathways have
been proposed to regulate MyHC isoform expression
(Chin et al., 1998; Bigard et al., 2000; Delling et al., 2000;
Naya et al., 2000), we also examined whether fiber-type
proportions are altered in NFATC2
 
2
 
/
 
2
 
 mice. Serial cross
sections of soleus muscles were stained with antibodies
recognizing type I or type II MyHC (Fig. 1 D, left). The
percentage of myofibers expressing type I MyHC is slightly
but significantly decreased by 5% in NFATC2
 
2
 
/
 
2
 
 muscles
compared with wild-type (Fig. 1 D, right). No difference
was noted in the percentage of myofibers expressing type
II MyHC (Fig. 1 D, right). Changes in one MyHC isoform
do not necessarily correlate with changes in another
MyHC isoform, since myofibers can coexpress different 
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MyHC isoforms. Thus, NFATC2 does not appear to play a
major role in regulating the expression of MyHC isoforms.
To determine if the reduced myofiber CSA in NFATC2
 
2
 
/
 
2
 
mice is specific to the soleus muscle or a generalized muscle
phenomenon, we analyzed myofiber CSA of TA and mas-
seter muscles. These muscles were chosen for analysis be-
cause they differ from the soleus in several properties. In
contrast with the soleus muscle, which is composed mainly
of type I and type IIA MyHC isoforms, the TA contains pri-
marily type IIb, and the masseter contains predominantly
type IIx MyHC (Eason et al., 2000). In addition, the mas-
seter exhibits differences in myoblast populations com-
pared with limb muscles (Pavlath et al., 1998). The myofi-
ber CSA of the TA is decreased 25% in NFATC2
 
2
 
/
 
2 
 
mice
compared with wild-type (Fig. 2). A similar decrease is ob-
served in the masseter (Fig. 2). These data suggest that
NFATC2 has a general role in regulating myofiber growth.
 
Myofiber Growth Is Defective in NFATC2
 
2
 
/
 
2
 
 Mice 
during Regeneration
 
During postnatal development and during regeneration
after injury, myofibers grow in size, a process involving ad-
dition of nuclei to the myofiber. Since myonuclei are post-
mitotic, myofiber growth involves the fusion of muscle
precursor cells with myofibers. These muscle precursor
 
cells, called satellite cells, lie underneath the basal lamina
surrounding each myofiber and are in close juxtaposition
to the myofiber itself. Satellite cells are normally quiescent
but become activated and start proliferating in response to
growth factors. Since satellite cells are required for skele-
tal muscle regeneration (Robertson et al., 1992; Quinlan et
al., 1997) and muscle growth (Darr and Schultz, 1989;
Rosenblatt and Parry, 1993; Mozdziak et al., 2000), we
used regenerating muscle as a model to examine satellite
cell function in NFATC2
 
2
 
/
 
2
 
 mice. Northern analysis was
performed on regenerating TA muscles of wild-type and
NFATC2
 
2
 
/
 
2
 
 mice on day 4 after injury using myoD and
myogenin as markers of activation/proliferation and dif-
ferentiation, respectively. At this time point, satellite cells
have become activated and are proliferating and begin-
ning to differentiate. No differences are observed in the
levels of either MyoD or myogenin mRNA (Fig. 3 A). In
addition, the number of myoblasts isolated from wild-type
and NFATC2
 
2
 
/
 
2
 
 muscles 2 d after regeneration does not
differ (data not shown), further suggesting that NFATC2
 
2
 
/
 
2
 
satellite cells are able to activate and proliferate nor-
mally. We next analyzed the ability of satellite cells to fuse
and form new myofibers. When myofibers form after in-
jury, their nuclei are centrally localized, facilitating identi-
fication of regenerating myofibers. The number of cen-
Figure 1. Reduced muscle size in NFATC22/2 so-
leus muscles is due to a decrease in myofiber CSA.
(A) A comparison of hematoxylin and eosin–
stained sections of wild-type and NFATC22/2 soleus
muscles clearly demonstrates the smaller size of the
mutant muscle (top). At higher magnification, CSA
of individual NFATC22/2 myofibers is also smaller
(bottom). (B) The CSA of both type I and type II
MyHC-expressing myofibers is reduced in the
NFATC22/2 muscles. (C) No difference exists in the
total number of myofibers in NFATC22/2 soleus
muscles compared with wild-type. (D) Representa-
tive sections immunostained with antibodies against
type I and type II MyHC are shown (left). A small
decrease in the percentage of myofibers expressing
type I MyHC occurs, but no difference exists in the
percentage of type II myofibers (right). Data are
mean 6 standard error; n 5 5–6 for wild-type and
n 5 5–6 for NFATC22/2 (*P , 0.05). Bars: (A, top)
200 mm; (A, bottom and D) 60 mm. 
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trally nucleated myofibers in the core of the injury 7 d
after injury was counted as described in Materials and
Methods. At this time point, the area of injury is com-
pletely filled with these regenerating myofibers. As seen in
Fig. 3 B, no significant difference exists in the number of
regenerated myofibers between wild-type and NFATC2
 
2
 
/
 
2
 
mice. Therefore, satellite cell function appears normal in
the early stages of muscle regeneration in the absence of
NFATC2.
To determine if NFATC2 regulates further growth of
regenerating myofibers, the CSA of regenerating myofi-
bers was measured at different times after injury. At day 7
after injury, the CSA of regenerating myofibers is the
same for both wild-type and NFATC2
 
2
 
/
 
2
 
. As further
growth of the regenerating myofibers occurs, the CSA of
myofibers in the mutant at each time point is significantly
decreased compared with wild-type (Fig. 3 C). At 50 d af-
ter injury, both wild-type and NFATC2
 
2
 
/
 
2
 
 myofibers are
almost completely recovered to the normal size for each
genotype (Fig. 2 A). However, the CSA of regenerating
wild-type and NFATC3
 
2
 
/
 
2
 
 myofibers is not different at
various time points after damage, indicating the specificity
of NFATC2 in regulating muscle growth (Fig. 3 C, bottom
inset). Taken together, these data demonstrate that myofi-
ber growth but not formation is impaired during regenera-
tion of NFATC22/2 mice. Thus, the function of NFATC2
is required for growth of myofibers as suggested by our
previous in vitro studies (Abbott et al., 1998).
Defects in Myofiber Growth in NFATC22/2 Mice 
Are Muscle Cell Intrinsic
Myofiber growth is dependent on both nonmuscle and
muscle cells. To determine if the defects observed in myo-
fiber growth in NFATC22/2 mice are intrinsic to mus-
cle cells, myoblasts were isolated from wild-type and
NFATC22/2 mice and studied in vitro. To determine if
NFATC22/2 myoblasts can differentiate normally, immu-
noblot analyses were performed on muscle cells in DM us-
ing antibodies against myogenin and EMyHC, markers of
myogenic commitment and differentiation, respectively
(Merlie and Gros, 1976; Andres and Walsh, 1996). Myoge-
nin levels increase at 24 h and are downregulated at 48 h in
both wild-type and NFATC22/2 cells (Fig. 4 A). A small
amount of myogenin is detected in both types of myo-
blasts, presumably due to spontaneous differentiation in
the cultures. EMyHC is expressed at similar levels in both
cell types after 24 and 48 h in DM. Thus, the expression
patterns of myogenin and EMyHC in wild-type and
NFATC22/2 muscle cells are similar, indicating that the
early stages of muscle differentiation are not regulated by
NFATC2. Consistent with these results, after 48 h in DM
wild-type and NFATC22/2 cultures appear morphologi-
cally differentiated, containing many multinucleated cells
with an elongated appearance. However, NFATC22/2
cells form myotubes that are smaller than wild-type myo-
tubes (Fig. 4 B), indicating a muscle-intrinsic role for
NFATC2 in regulating myotube size.
Figure 2. Myofiber CSA in other muscles is also reduced in
NFATC22/2 mice. The CSA of individual myofibers was measured
in TA and masseter muscles of wild-type and NFATC22/2 mice.
Data are mean 6 standard error; n 5 5–8 for wild-type and n 5 3
for NFATC22/2 (*P , 0.05).
Figure 3. Regenerating myofibers form, but their growth is im-
paired in NFATC22/2 mice. (A) Northern blots of TA muscles
from wild-type and NFATC22/2 mice 4 d after injury are shown.
A portion of an ethidium bromide–stained gel containing 28S and
18S rRNAs demonstrates relative RNA loading. (B) 7 d after in-
jury, TA muscles were collected from wild-type and NFATC22/2
mice, and the number of regenerated myofibers was counted in
sections from the central region of the lesion. (C) A comparison
of hematoxylin and eosin–stained sections of regenerating TA
muscles at day 25 after injury demonstrates the smaller size of the
mutant myofibers (top). The CSA of regenerated myofibers in
the central region of the lesion was determined for various time
points after injury (bottom). Data are mean 6 standard error;
n 5 3–7 for each genotype (*P , 0.05). Bar, 60 mm.The Journal of Cell Biology, Volume 153, 2001 334
Since myofiber size correlates with myonuclear number
(Allen et al., 1999), the formation of smaller myotubes
could result from defects in either myoblast–myotube fu-
sion or myotube–myotube fusion. Thus, assays were per-
formed on myotube cultures after 48 h in DM to compare
the number of nuclei within wild-type and NFATC22/2 myo-
tubes. To clearly define the nuclei within myotubes, the
myotubes were immunostained for EMyHC and the num-
ber of nuclei within individual myotubes (at least two nu-
clei) was counted. Myotubes were grouped into two catego-
ries, those with two to four nuclei and those with five or
more nuclei. The percentage of the myotubes in each cate-
gory was calculated. The majority of NFATC22/2 myotubes
contain two to four nuclei (Fig. 4 C), whereas wild-type
myotubes are equally distributed between the two nuclear
groupings. In addition, an increased number of myotubes
occurs in the mutant cultures (data not shown). These re-
sults suggest that NFATC22/2 muscle cells can differentiate
and fuse to form the initial multinucleated cell but are un-
able to recruit the fusion of myoblasts or myotubes effi-
ciently and thus remain small compared with wild-type
myotubes. The increased number of myotubes in the
NFATC22/2 cultures suggests that if myoblasts are not re-
cruited into growing myotubes, they differentiate and fuse
with other myoblasts, thus forming many small myotubes.
Alternatively, many small myotubes could result from an
inability of NFATC22/2 myotubes to fuse with one another.
Retroviral Expression of NFATC2 Rescues the Defects 
in Myotube Size and Nuclear Number
To confirm that the absence of NFATC2 is responsible for
the observed defects in myotube size and nuclear number
in vitro, two types of experiments were performed. First,
the expression levels of other NFAT isoforms in the mu-
tant cells were analyzed to rule out compensatory changes
that could contribute to defects in myotube size. We ana-
lyzed the expression of the three other known calcium-
responsive NFAT isoforms, NFATC1, NFATC3, and
NFATC4, in wild-type and NFATC22/2 cells. RT-PCR
was performed on RNA isolated from high-density wild-
type and NFATC22/2 myoblasts using gene-specific prim-
ers and normalized to the expression of 18S RNA.
NFATC4 was not detected in either genotype (data not
shown). The expression of NFATC1 and NFATC3 is not
significantly different between the two types of muscle
cells (Fig. 5 A). Thus, the absence of NFATC2 does not al-
ter the expression of NFATC1 or NFATC3 in skeletal
muscle cells. These results are consistent with the results
of Ranger et al. (2000), indicating that no compensatory
changes occur in the expression of individual NFAT iso-
forms in chondrocytes lacking NFATC2.
In the second line of experiments, NFATC22/2 myo-
blasts were infected with a retrovirus expressing NFATC2
to determine if expression of NFATC2 could rescue the
reduced size and nuclear number of NFATC22/2 myo-
tubes. Initially, the activity of the recombinant NFATC2
was demonstrated in wild-type cells containing an NFAT-
responsive reporter construct (Fig. 5 B). Myoblasts in-
fected with either control or NFATC2 retroviruses were
induced to differentiate, and luciferase activity was deter-
mined. Luciferase activity is increased in NFATC2-infected
cells by approximately sevenfold, confirming the transcrip-
tional activity of the recombinant NFATC2 in skeletal
muscle cells. Subsequently, nuclear number assays were
performed on myotubes in wild-type and NFATC22/2 cul-
tures infected with either control or NFATC2 retrovirus.
No significant difference is observed in nuclear number of
wild-type cells infected with either control or NFATC2
retrovirus (data not shown), suggesting that overexpress-
ing NFATC2 in wild-type muscle cells does not affect size
or nuclear number of myotubes. However, NFATC22/2
muscle cells infected with the NFATC2 retrovirus form
myotubes similar in size to wild-type myotubes (Fig. 5 C)
and with nuclear number proportions similar to wild-type
(Fig. 5 D). Together, these results show that the absence of
NFATC2 is responsible for the defects in myotube size
and nuclear number in NFATC22/2 cells.
Myonuclear Number Is also Decreased in NFATC22/2 
Soleus Muscles
The reduced number of nuclei in NFATC22/2 myotubes
suggests that NFATC22/2 myofibers in vivo may also have
reduced myonuclei. To determine if myonuclear number is
reduced in NFATC22/2 myofibers, cross sections of soleus
muscles were immunostained with dystrophin to outline
the myofiber sarcolemma and stained with DAPI to label
nuclei (Fig. 6 A). Nuclei inside the outline of dystro-
phin were counted in wild-type and NFATC22/2 soleus
muscles. A 50% decrease in myonuclei is observed in
NFATC22/2 soleus muscles compared with wild-type (Fig.
Figure 4. NFATC22/2 myo-
blasts form small myotubes
with decreased nuclear num-
ber in vitro. (A) Cellular pro-
teins from wild-type and
NFATC22/2 myoblasts were collected at various time points dur-
ing differentiation and analyzed by immunoblotting for myoge-
nin and EMyHC. The expression patterns of myogenin and
EMyHC are similar between differentiating wild-type and
NFATC22/2 muscle cells. A portion of a Coomassie-stained gel
demonstrates relative protein loading. (B) Wild-type and
NFATC22/2 myoblasts were induced to differentiate in DM for
48 h and then immunostained for EMyHC. (C) The number of
nuclei within individual myotubes (at least two nuclei) was
counted. Myotubes were grouped into two categories, and the
percentage of myotubes in each category was determined. Each
bar represents mean 6 standard error of three independent cell
isolates each performed in duplicate (*P , 0.05). Bar, 60 mm.Horsley et al. NFATC2 Regulates Nuclear Number and Size of Myotubes 335
6 B). These data correlate with the in vitro results, show-
ing that NFATC22/2 myotubes have fewer nuclei than
wild-type myotubes. Since fusion of myoblasts and thus
addition of myonuclei is required for growth of mamma-
lian myofibers (Darr and Schultz, 1989; Rosenblatt and
Parry, 1993; Mozdziak et al., 2000), these data also suggest
that the reduced CSA of myofibers in NFATC22/2 mice
results from defects in the ability of muscle cells to fuse
with the myofiber and to add nuclei to the myofiber.
Discussion
We have shown previously that individual NFAT proteins
translocate to the nucleus of muscle cells at specific stages
of myogenesis (Abbott et al., 1998). Since NFATC2 trans-
locates to the nucleus only in newly formed myotubes, we
examined whether NFATC2 has a role in muscle growth
using NFATC22/2 mice. Histological analyses of soleus
muscles of adult NFATC22/2 mice revealed that the mu-
tant mice have smaller soleus muscles due to a decrease in
the CSA of myofibers. Other muscles with divergent func-
tions, MyHC composition, and embryonic origins, such as
the TA and masseter, also exhibit decreases in myofiber
CSA in NFATC22/2 mice. To determine if this defect is
due to impaired myofiber growth, we examined regenerat-
ing skeletal muscle as a model for myofiber growth. In-
jured muscles in NFATC22/2 mice can form new myofibers
normally, but subsequent myofiber growth is impaired.
Defects in myofiber growth are intrinsic to muscle cells
since cultured muscle cells lacking NFATC2 form small
myotubes with few nuclei. Retroviral expression of recom-
binant NFATC2 in the mutant muscle cells rescues the de-
fects in myotube size and nuclear number, indicating that
the lack of NFATC2 is responsible for the observed cellu-
lar phenotype of NFATC22/2 cells. The reduction in the
number of myonuclei in vitro is also found in vivo in myofi-
bers of NFATC22/2 mice. Taken together, these data im-
plicate a novel role for NFATC2 in skeletal muscle growth.
Muscle growth results from an ordered sequence of
events. Withdrawal of mitogens in vitro causes myoblasts
to exit the cell cycle and activate the expression of differen-
tiation specific genes. Subsequently, myoblasts migrate to-
ward one another, elongate, align, and through cell–cell in-
teractions fuse together to form a multinucleated cell.
Multiple proteins are required for migration and fusion of
myoblasts such as integrins and other cell adhesion mole-
cules, metalloproteases, and phospholipases (Knudsen,
1992). In addition, increases in intracellular calcium (Con-
Figure 5. The lack of NFATC2 in mutant myotubes
is responsible for the cellular phenotype. (A) RT-
PCR of RNA from wild-type and NFATC22/2 myo-
blasts was performed for various NFAT isoforms
and normalized to the expression of 18S rRNA.
NFATC4 is not expressed in myoblasts of either
genotype (data not shown). Data are mean 6 stan-
dard error; n 5 3 for each genotype. (B) Primary
myoblasts were infected with an NFAT-responsive
reporter and either control (Ctrl) or NFATC2 ret-
roviruses. Cells were induced to differentiate, and
luciferase assays were subsequently performed.
Data are reported as fold increase in luciferase ac-
tivity over control cells. Each bar represents the
mean  6 standard error of four independent experi-
ments each performed in triplicate (*P , 0.05). (C)
Wild-type and NFATC22/2 myoblasts were infected
with either control or NFATC2 retroviruses (RV) and induced to differentiate for 48 h.
NFATC22/2 cultures infected with NFATC2 retrovirus display increased myotube size
with an increased number of nuclei. (D) The number of nuclei within individual myotubes
(at least two nuclei) was counted for each of the retrovirally infected cultures. Myotubes
were grouped into two categories as in the legend to Fig. 4 C, and the percentage of myo-
tubes in each category was calculated. The expression of NFATC2 in NFATC22/2 cultures
returns the nuclear number proportions back to that of wild-type distributions. Each bar
represents mean 6 standard error of three experiments each performed in duplicate
(**significantly different from 1/1 Ctrl P , 0.05; *significantly different from 2/2 Ctrl
P , 0.05). Bar, 60 mm.The Journal of Cell Biology, Volume 153, 2001 336
stantin et al., 1996) and several calcium-dependent mole-
cules (Barnoy et al., 1996; Gorza and Vitadello, 2000) are
essential for myoblast fusion, including calmodulin (Kim et
al., 1992), which can regulate calcineurin. Once myotubes
form, additional myoblasts fuse with the myotube, and the
myotube grows in size. Postnatal muscle growth in vivo is
also characterized by myoblast fusion with myofibers, lead-
ing to an increase in myonuclear number. Numerous stud-
ies indicate that myoblasts are critical for muscle growth in
vivo. When the proliferative capacity of myoblasts is atten-
uated, increases in myonuclear number and myofiber size
are blocked in growing rats (Darr and Schultz, 1989;
Rosenblatt and Parry, 1993; Mozdziak et al., 2000). Addi-
tionally, the lack of myoblast growth factors such as leuke-
mia inhibitory factor (Kurek et al., 1997) leads to reduc-
tions in the size of myofibers after regeneration. Thus,
numerous molecules contribute to proper muscle cell size.
Our data indicate that NFATC2 is involved in muscle
growth. Myoblast proliferation and differentiation occur
normally in NFATC22/2 muscle. However, the reduced
number of nuclei in NFATC22/2 myotubes and myofibers
suggests that a later stage involving the fusion of differen-
tiated muscle cells with the multinucleated muscle cell is
impaired. The decrease in the number of nuclei is corre-
lated with a decrease in myotube size, implicating an
NFATC2-dependent pathway in the control of myotube
size. Since a few NFATC22/2 myotubes do form with large
number of nuclei, NFATC2-independent pathways for
muscle growth also must exist. However, the majority of
NFATC22/2  myotubes do not have increased nuclear
number and are small in size. Thus, the downstream tar-
gets of NFATC2 allow the fusion of differentiated muscle
cells with newly formed myotubes and the subsequent
growth of the myotube. In addition, our data suggest that
fusion of differentiated muscle cells with myotubes/myofi-
bers is distinct from the initial fusion of myoblasts to form
a multinucleated muscle cell.
Based on our results, we present the model outlined in
Fig. 7 for the NFATC2-mediated signaling pathway that
leads to muscle growth. Increases in intracellular calcium
lead to the activation of calcineurin. Calcineurin dephos-
phorylates NFATC2 in newly formed myotubes, permit-
ting nuclear translocation of NFATC2. Once in the nu-
cleus, NFATC2 along with other transcription factors
influences gene transcription. NFATC2 may either directly
or indirectly regulate gene transcription of a cell surface
protein (pathway 1) that mediates cell–cell interaction or
cell fusion between mononucleated muscle cells and newly
formed myotubes. Evidence exists for cell surface proteins
that mediate the fusion of myoblasts with myotubes. The
integrin very late antigen 4 on multinucleated muscle cells
and its counterreceptor vascular cell adhesion molecule 1
on myoblasts are thought to mediate myoblast fusion with
myofibers during development (Rosen et al., 1992). In ad-
dition, glycoproteins may mediate myoblast–myotube in-
teractions to allow fusion and muscle growth, since wheat
germ agglutinin can block myoblast fusion with myotubes
and decrease myotube size (Muroya et al., 1994). Alterna-
tively, NFATC2 could either directly or indirectly regulate
gene transcription of a secreted protein (pathway 2) that
recruits differentiated mononucleated myoblasts to fuse
with adjacent myotubes. Secreted factors apparently can
regulate the fusion of cells with myotubes. Fibroblasts co-
cultured with young or old myotubes can acquire myogenic
characteristics and fuse with myotubes (Breton et al.,
1995), suggesting that a secreted factor from the myotube
recruits fibroblast fusion. Though not shown, both path-
way 1 and 2 could also mediate myotube–myotube fusion.
Specific molecules downstream from NFATC2 that con-
tribute to muscle growth, though not examined in this
study, are currently being investigated.
Our data suggest that multinucleated muscle cells may
regulate the fusion of myoblasts/myotubes. Myotube–
Figure 6. Myonuclear num-
ber is reduced in NFATC22/2
myofibers. (A) A representa-
tive wild-type myofiber immunostained with an antibody against
dystrophin (red) and stained with DAPI (blue) illustrates the
myonuclear number assay. Arrow indicates a myonucleus within
the dystrophin border, and arrowheads indicate nuclei outside
the myofiber. (B) DAPI-stained nuclei within the dystrophin-posi-
tive sarcolemma were counted in soleus muscles from wild-type
and NFATC22/2 mice, and the number of myonuclei was ex-
pressed per 100 myofibers. Data are mean 6 standard error; n 5
6 for each genotype (*P , 0.05). Bar, 20 mm. 
Figure 7. Model for the role of NFATC2 in the
growth of myotubes. Increases in intracellular
calcium activate the phosphatase calcineurin,
which dephosphorylates NFATC2 in nascent
myofibers causing nuclear translocation of
NFATC2. Myofibers lacking NFATC2 have re-
duced nuclear number and size. Thus, the
downstream targets of NFATC2 recruit fusion
of myoblasts/myotubes with multinucleated
muscle cells and contribute to increases in mus-
cle size. Only myoblast fusion is represented in
the model. NFATC2 may regulate a cell surface protein (pathway 1) that mediates cell–cell interaction or cell fusion between differ-
entiated muscle cells and newly formed myofibers. Alternatively, NFATC2 could regulate gene transcription of a secreted protein
(pathway 2) that recruits differentiated muscle cells to fuse with adjacent myofibers.Horsley et al. NFATC2 Regulates Nuclear Number and Size of Myotubes 337
myotube fusion has been suggested to occur during regen-
eration (Robertson et al., 1990), but nothing is known about
its regulation. Several lines of evidence implicate multinu-
cleated cells as controlling the site and extent of myoblast
fusion. During the development of mammalian skeletal
muscle, primary myofibers form initially and are followed
by the formation of secondary myofibers. Primary myofi-
bers control the site of secondary myofiber assembly, since
secondary myofibers form only at the site of innervation
on the primary myofiber, independently of the nerve
(Duxson et al., 1989; Duxson and Sheard, 1995). In addi-
tion, the primary myofiber seems to restrict the fusion of
secondary myoblasts, whereas the secondary myofiber
seems to recruit fusion, since secondary myoblasts fuse
primarily with the forming secondary myofiber (Harris et
al., 1989; Zhang and McLennan, 1995). This specificity of
fusion shares analogy with Drosophila muscle develop-
ment in which founder myoblasts express dumbfounded,
an attractant for myoblast fusion, and recruit fusion-com-
petent myoblasts to fuse with founder myoblasts and not
with other myoblasts (Ruiz-Gomez et al., 2000). The
mechanisms used by founder myoblasts may share similar-
ities with how a newly formed myotube or myofiber re-
cruits myoblasts/myotubes to fuse. Further suggesting that
myofibers can control the location of myoblast fusion,
myofibers elongate by fusion of myoblasts at their ends
during mammalian postnatal growth (Williams and Gold-
spink, 1971; Zhang and McLennan, 1995). The mech-
anisms by which myofibers regulate the fusion of myo-
blasts are unknown but may involve expression of proteins
such as those mentioned above. This control of fusion by
multinucleated muscle cells is likely one mechanism by
which the size of muscle cells is regulated.
Since increased intracellular calcium activates NFATC2
only in newly formed myotubes (Abbott et al., 1998) and
calcineurin is the only known phosphatase that can control
nuclear translocation of NFAT proteins, NFATC2 is likely
regulated by calcineurin to control myotube/myofiber
growth. Calcineurin has been shown to be involved in skel-
etal muscle hypertrophy (Musaro et al., 1999; Semsarian et
al., 1999; Dunn et al., 2000). The inability of NFATC2
overexpression to induce an increase in myotube size and
nuclear number in wild-type myotubes suggests that
NFATC2 is not involved in skeletal muscle hypertrophy.
Several possibilities exist to explain this lack of effect on
growth of wild-type myotubes. (a) Calcineurin may not ac-
tivate the recombinant NFATC2 once myotubes reach a
certain state of maturity, after the addition of further myo-
nuclei. This hypothesis is supported by the fact that
NFATC2 cannot be activated by a calcium ionophore in
mature myotubes (Abbott et al., 1998). (b) Other conver-
gent pathways may be necessary for NFATC2-mediated
effects on cell growth. These pathways could involve the
activation of additional transcription factors necessary for
forming a transcriptional complex with NFATC2. (c)
Changes may occur in unfused myoblasts or myotubes
with time such that they are either no longer responsive to
a putative secreted factor regulated by NFATC2 or they
downregulate a cell surface molecule necessary for fusion
with myotubes. (d) Limits may exist on the size of primary
myotubes in culture. Thus, wild-type myotubes already
may be at their maximal cell size and no further increases
are possible even in the presence of the recombinant
NFATC2. Further work is needed to define the relation of
NFATC2-dependent muscle growth with hypertrophy.
In summary, we demonstrate that the calcium-regulated
transcription factor NFATC2 regulates muscle growth.
These data implicate an NFAT-dependent pathway in
newly formed myotubes that controls further cell fusion in
a mechanism that is distinct from the initial formation of
multinucleated muscle cells. Myoblast fusion with multi-
nucleated cells is central to proper muscle development
but is also clinically relevant. Enhancing myoblast fusion
with multinucleated cells has potential therapeutic value
by improving the fusion of endogenous myoblasts in the
treatment of muscle injuries or muscle atrophy or by en-
hancing the fusion of exogenous transplanted myoblasts in
gene therapy protocols (Blau and Springer, 1995). Both
myotonic dystrophy (Farkas-Bargeton et al., 1988) and
centronuclear myopathy (Wockel et al., 1998) are charac-
terized by reduced myofiber size, suggesting that myoblast
fusion may be defective in these muscle disorders. Further
studies will be directed towards identifying genes regu-
lated by NFATC2 and their regulation of the fusion of dif-
ferentiated muscle cells with multinucleated muscle cells.
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